Mesoblast reports financial results and operational highlights for fiscal year ended june 30, 2022

New york, aug. 30, 2022 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and operational highlights for the period ended june 30, 2022 and provided an update on upcoming milestones.
MESO Ratings Summary
MESO Quant Ranking